ArticleFrontiers in pharmacology2018
Magnoflorine Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Suppressing NF-κB and MAPK Activation.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 94 citations in OpenAlex.
- Magnoflorine and its structural diversity: mechanisms, and drug discovery opportunities a review.Molecular diversity · 2026Review
- Exploration of the therapeutic potential of magnoflorine against osteoarthritis progression using network pharmacology and in vitro validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Enrichment of Alkaloids fromFoods (Basel, Switzerland) · 2026Article
- Decoding Barberry Root's Therapeutic Network: A Synergistic Solution for IBS-D.Combinatorial chemistry & high throughput screening · 2026Article
- Obtusifolin mitigates acute lung injury and improves cardio-pulmonary functions in acute lung injury model by modulating oxidative stress and NF-κB signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Modulation of Toll-like Receptors with Natural Compounds: A Therapeutic Avenue Against Inflammaging?International journal of molecular sciences · 2025Review
- Advances in Atopic Dermatitis Treatment: From Pathogenesis to Natural Product-Based Therapies.Phytotherapy research : PTR · 2025Review
- The mechanism of p38 MAPK, NF-κB, and IL-6 in T-2 toxin and/or selenium deficiency induced spleen injury.Immunologic research · 2025Article
- Fevogrit, a polyherbal medicine, mitigates endotoxin (lipopolysaccharide)-induced fever in Wistar rats by regulating pro-inflammatory cytokine levels.Animal models and experimental medicine · 2025Article
- Luteolin Alleviates Inflammation Induced byVeterinary sciences · 2025Article
- The Phytochemical Profile of the Petroleum Ether Extract ofInternational journal of molecular sciences · 2024Article
- Magnoflorine ameliorates hepatic fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway.Heliyon · 2024Article
- Magnoflorine attenuates Ang II-induced cardiac remodeling via promoting AMPK-regulated autophagy.Cardiovascular diagnosis and therapy · 2024Article
- Article
- Magnoflorine Ameliorates Collagen-Induced Arthritis by Suppressing the Inflammation Response via the NF-κB/MAPK Signaling Pathways.Journal of inflammation research · 2023Article
- Methyl p‑hydroxycinnamate exerts anti‑inflammatory effects in mouse models of lipopolysaccharide‑induced ARDS.Molecular medicine reports · 2022Article
- PEP-sNASP Peptide Alleviates LPS-Induced Acute Lung Injury Through the TLR4/TRAF6 Axis.Frontiers in medicine · 2022Article
- Poldip2/Nox4 Mediates Lipopolysaccharide-Induced Oxidative Stress and Inflammation in Human Lung Epithelial Cells.Mediators of inflammation · 2022Article
- The Analgesic Properties ofMolecules (Basel, Switzerland) · 2021Review
- Paeoniflorin improves myocardial injury via p38 MAPK/NF-KB p65 inhibition in lipopolysaccharide-induced mouse.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) which is featured by a strong pulmonary inflammation, is a major cause of morbidity and mortality in critically ill patients. Magnoflorine, a quaternary alkaloid isolated from Chinese herb Magnolia or Aristolochia, has been reported to have potent anti-inflammatory properties. However, the effect of magnoflorine on lipopolysaccharide (LPS)-induced ALI in mice has not been reported. The purpose of the present study is to investigate the anti-inflammatory effect of magnoflorine on LPS-induced ALI and elucidate its possible molecular mechanisms in RAW264.7 cells. The results of histopathological changes as well as the myeloperoxidase (MPO) activity indicated that magnoflorine significantly alleviated the lung injury induced by LPS. In addition, qPCR results showed that magnoflorine dose-dependently decreased the expression of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. Immunofluorescence assay also confirmed that the level of Toll-like receptor 4 (TLR4) induced by LPS was inhibited by magnoflorine treatment. Further experiments were performed using Western blotting to detect the expression of related proteins in the NF-κB and MAPK signaling pathways. The results showed that magnoflorine suppressed the levels of phosphorylated p65, IκBα, p38, ERK, and JNK. In conclusion, all data indicate that magnoflorine could protect against LPS-induced inflammation in ALI at least partially by inhibiting TLR4-mediated NF-κB and MAPK signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.